Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
The latest announcement is out from Tsumura & Co ( (JP:4540) ).
Tsumura & Co. has revised its earnings forecast for the fiscal year ending March 31, 2025, citing a slower-than-expected recovery in domestic sales of Kampo formulations and lower sales in its Chinese crude drugs segment. Despite a drop in net sales, the company projects higher ordinary profit and profit attributable to owners, largely due to depreciation of the yen and gains on the sale of investment securities. The upward revision in profits demonstrates the company’s ability to manage costs effectively, although it faces challenges in boosting sales.
More about Tsumura & Co
Tsumura & Co. operates in the pharmaceutical industry, specializing in Kampo medicine, which is a traditional Japanese herbal medicine. The company is known for its production and sale of Kampo formulations and crude drugs, with a market focus that includes both domestic and Chinese markets.
YTD Price Performance: -3.64%
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $2.23B
See more insights into 4540 stock on TipRanks’ Stock Analysis page.
